HIGH IMPACT - Madrigal reported positive topline data from the double-blind portion of the its phase 3 MAESTRO-NAFLD study of resmetirom in NASH. Patients in the study were identified based on non-invasive imaging and biomarkers, and were treated…
https://inthought.com/wp-content/uploads/2022/03/blank-transparent.png720720old adminhttps://inthought.com/wp-content/uploads/2019/03/inThought-Logo-Transparent-3.7.pngold admin2022-01-31 00:00:062022-04-13 21:07:04Madrigal reports positive results from phase 3 MAESTRO-NAFLD study of resmetirom
HIGH IMPACT - During Roche’s HDSA presentation, the company discussed GENERATION-HD1 trial data and post-hoc analysis in subgroups of patients. The call was led by Peter McColgan (Roche) and Lauren Boak (Roche). The speaker mentioned that…
HIGH IMPACT - Poseida announced in its Q3 press release that it will end its P-BCMA-101 autologous CAR-T program and prioritize its allogeneic CAR-T P-BCMA-ALLO1. “While we believe the P-BCMA-101 autologous program has competitive advantages…
HIGH IMPACT - Reata has submitted an NDA to the FDA for bardoxolone methyl for the treatment of chronic kidney disease caused by Alport Syndrome. Reata has requested priority review for the application. The submission was based on the results…
HIGH IMPACT - During its Q4 2020 earnings call, Prothena gave an update on its prasinezumab clinical program for Parkinson’s disease. During the clinical overview, Prothena highlighted that prasinezumab specifically targets the C-terminus…
HIGH IMPACT - Both Pfizer and Amgen provided updates on its BCMA bispecific programs in Q4/FY 2020 earnings calls on February 2. Pfizer’s BCMAxCD3 bispecific, elranatamab (PF-06863135), received FDA Fast Track designation in late January…
https://inthought.com/wp-content/uploads/2019/03/inThought-Logo-Transparent-3.7.png00old adminhttps://inthought.com/wp-content/uploads/2019/03/inThought-Logo-Transparent-3.7.pngold admin2021-02-03 20:26:402022-03-04 21:18:39BCMA Bispecific Earnings Roundup: Pfizer’s Elranatamab Granted FDA Fast Track Designation While Amgen’s Pavurutamab Trial is Paused Due to Safety